The rationale for such an approach was our earlier demonstration of low TGR5 activation capacity in the enterohepatic cycle of HFD-fed foz/foz mice with NASH, with a pathogenic contribution to liver disease [22]. The gene discussed is GPBAR1; the disease is metabolic dysfunction-associated steatohepatitis.